From Nasdaq: 2024-11-12 19:00:03

Ginkgo Bioworks Holdings, Inc. reported a quarterly loss of $1.08 per share, beating the Zacks Consensus Estimate of a loss of $2.40. The company posted revenues of $89.05 million, surpassing estimates by 102.77%. The stock has underperformed, losing 87% this year. Future stock performance will rely on earnings outlook and management commentary.

Patterson Cos. is expected to report quarterly earnings of $0.49 per share, a decrease of 2% from last year. Revenue is projected to be $1.64 billion, down 0.7% from the previous year. Analysts have revised estimates lower over the past 30 days. Investors are advised to monitor industry outlook and Zacks Rank for future performance.

Ginkgo Bioworks and Patterson Cos. are both in the medical sector. Ginkgo Bioworks’ earnings outlook is unfavorable, resulting in a Zacks Rank #4 (Sell). Patterson Cos.’s earnings and revenue are expected to decline. Investors should stay informed about industry trends and earnings estimate revisions for both stocks.

Research Chief identifies Ginkgo Bioworks Holdings, Inc. as a potential stock to watch. The company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter. A recent pullback in the stock price presents an opportunity for investors to potentially benefit from its explosive upside potential.



Read more at Nasdaq: Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates